It is reported that dysregulation of AXL expression is very common in the resistance of tumor cells to EGFR TKIs, the up-regulation of AXL can be detected after the first generation EGFR TKIs gefitinib, erlotinib 31 and the third generation EGFR TKI Osimertinib 32 acquired resistance. The gene discussed is EGFR; the disease is neoplasm.